NHS England has finalised and expanded its delayed MedTech Funding Mandate, an initiative intended to increase uptake of medtech products. The initiative aims to raise awareness throughout the UK healthcare system of medical devices, digital products and diagnostics and how they can save the NHS money.
The mandate was originally due to go live in April 2020 before being postponed due to the COVID-19 pandemic. The initiative is now scheduled to start from April 2021, a delay that has enabled NHS England to expand the scheme.
Originally, the scheme was planned to launch with three products: Roche and Quidel’s Placental Growth Factor (PGIF)-based pre-eclampsia test; SecurAcath, a percutaneous catheter securing device from Interrad Medical; and HeartFlow, a device for estimating fractional flow reserve from the medtech of the same name.
Under the original scheme, NHS England predicted that these three products could save the healthcare system around £20 million over the course of five years.
Following the COVID-19-related delay, NHS England was able to add a fourth device to the MedTech Funding Mandate: electroCore’s gammaCore, a migraine and cluster headache treatment. gammaCore had only just received a positive publication from NICE, the healthcare watchdog, when the initial consultation began, meaning it was ineligible for the first planned year of the initiative.